Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

DVT

- PMLiVE

AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use

An estimated 7.2 million people in the UK are living with the progressive condition

- PMLiVE

Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials

The candidate is currently under review for both interstitial lung diseases in the EU and US

- PMLiVE

NHS patients to access Theramex’s endometriosis pill following NICE recommendation

The once-a-day drug has been recommended for patients with a history of previous medical or surgical treatment

- PMLiVE

Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m

The companies will focus on developing treatments for hard-to-treat ALT-positive tumours

- PMLiVE

BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

- PMLiVE

Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m

The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys

- PMLiVE

AstraZeneca’s Truqap recommended by NICE to treat advanced breast cancer

NICE estimates that around 1,100 patients will benefit from the twice-a-day tablet

- PMLiVE

Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

Around 800 people in the UK are diagnosed with late-stage disease every year

- PMLiVE

NICE recommends Pharming’s Joenja as first treatment for ultra-rare immune disease APDS

Approximately 40 to 50 people in the UK are known to be living with the inherited disorder

- PMLiVE

Boehringer Ingelheim and Salipro Biotech enter drug development partnership

The companies will focus on targeting proteins in areas such as cardio-renal-metabolic diseases

- PMLiVE

World Kidney Day – Boehringer launches CKD initiative to tackle UK health inequalities

Approximately 10% of the UK population is affected by chronic kidney disease

- PMLiVE

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

Around 1,000 patients could benefit from the relugolix combination therapy every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links